National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI
Childhood Cerebral Astrocytoma/Malignant Glioma Treatment (PDQ®)
Patient VersionHealth Professional VersionEn españolLast Modified: 04/09/2008



Purpose of This PDQ Summary






General Information







Cellular Classification






Stage Information






Treatment of Low-Grade Childhood Cerebral Astrocytoma






Treatment of High-Grade Childhood Cerebral Astrocytoma






Recurrent Childhood Cerebral Astrocytoma






Get More Information From NCI






Changes to This Summary (04/09/2008)






More Information



Page Options
Print This Page  Print This Page
Print This Document  Print Entire Document
View Entire Document  View Entire Document
E-Mail This Document  E-Mail This Document
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
New Study of Targeted Therapies for Breast Cancer

The Nation's Investment in Cancer Research FY 2009

President's Cancer Panel Annual Report: 2006-2007

Cancer Trends Progress Report: 2007 Update

Past Highlights
HPV Vaccines for Cervical Cancer
Cellular Classification

Various classification schemata have been used to separate glial tumors into prognostic subsets.[1] According to the most recent classification of the World Health Organization, glial tumors are divided on the basis of histologic criteria into the following subsets: pilocytic astrocytomas, low-grade nonpilocytic astrocytomas, anaplastic gliomas, and glioblastoma multiforme.[2] Various types of nonpilocytic astrocytomas, such as fibrillary protoplasmic and gemistocytic, have been identified. Both malignant and benign varieties of oligodendrogliomas may occur. In young children (especially those younger than 1 year at diagnosis), new variants such as dysembryoplastic neuroepithelial tumor and desmoplastic infantile gangliogliomas are increasingly recognized. Mixed gliomas are classified separately, as are gangliogliomas and other primary neuronal tumors. In general, the grade of the tumor is predictive of outcome; patients with higher-grade tumors have a poorer prognosis. High-grade gliomas with p53 expression and mutation are also associated with a poorer prognosis.[3] MIB-1 labeling index, a marker of cellular proliferative activity, is predictive of outcome in childhood malignant brain tumors. Both histologic classification and proliferative activity evaluation have been shown to be independently associated with survival.[4]

References

  1. Burger PC, Sheithauer BW, Vogel FS: Surgical pathology of the nervous system and its coverings. 3rd ed. New York, NY: Churchill Livingstone, 1991. 

  2. Kleihues P, Cavenee WK, eds.: Pathology and Genetics of Tumours of the Nervous System. Lyon, France: International Agency for Research on Cancer, 2000. 

  3. Pollack IF, Finkelstein SD, Woods J, et al.: Expression of p53 and prognosis in children with malignant gliomas. N Engl J Med 346 (6): 420-7, 2002.  [PUBMED Abstract]

  4. Pollack IF, Hamilton RL, Burnham J, et al.: Impact of proliferation index on outcome in childhood malignant gliomas: results in a multi-institutional cohort. Neurosurgery 50 (6): 1238-44; discussion 1244-5, 2002.  [PUBMED Abstract]

Back to TopBack to Top

< Previous Section  |  Next Section >


A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov